Drug search by name

Pralatrexate Intravenous and Renal impairment

Result of checking the interaction of drug Pralatrexate Intravenous and disease Renal impairment for safety when used together.

Check result:

Pralatrexate Intravenous <> Renal impairment

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Patients with moderate to severe renal function impairment may be at greater risk of toxicity due to increased exposure. Patients should be monitored for renal function and toxicity and dosage should be adjusted accordingly. For patients with severe renal impairment (GFR 15 to <30), the recommended dose of pralatrexate is 15 mg/m2. Avoid the use of pralatrexate in patients with ESRD undergoing dialysis, unless the potential effect justifies the potential risk.

Pralatrexate Intravenous

Generic Name: pralatrexate

Brand Name: Folotyn

Synonyms: Pralatrexate (Intravenous), PRALAtrexate, Pralatrexate

What is Pralatrexate Intravenous?